Microangiopathic antiphospholipid antibody syndrome due to anti-phosphatidylserine/prothrombin complex IgM antibody.

Abstract

Herein we describe a case of microangiopathic antiphospholipid syndrome (MAPS) due to anti-phosphatidylserine/prothrombin complex (aPS/PT) IgM antibody successfully treated with rituximab. A significant correlation was observed between the clinical course and the aPS/PT IgM antibody titer, which can rise earlier before the appearance of clinical symptoms. Rituximab can be safely and effectively used for MAPS. Although detection of only aPS/PT IgM antibody is rare, aPS/PT IgM antibody might be associated with the pathogenesis of MAPS and might be a useful marker of disease activity.

• Authors: Yumi Senda, Kazuhide Ohta, Tadafumi Yokoyama, Masaki Shimizu, Kengo Furuichi, Takashi Wada, Akihiro Yachie
• Journal: Pediatrics international : official journal of the Japan Pediatric Society (Pediatr Int) Vol. 59 Issue 3 Pg. 378-380 (Mar 2017) ISSN: 1442-200X [Electronic] Australia
• PMID: 28317300 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2017 Japan Pediatric Society.

Chemical References

• Autoantibodies
• Biomarkers
• Immunoglobulin M
• Immunologic Factors
• Phosphatidylserines
• Rituximab
• Prothrombin

Topics

• Antiphospholipid Syndrome (blood, diagnosis, drug therapy, immunology)
• Autoantibodies (blood)
• Biomarkers (blood)
• Child
• Female
• Humans
• Immunoglobulin M (blood)
• Immunologic Factors (therapeutic use)
• Phosphatidylserines (immunology)
• Prothrombin (immunology)
• Rituximab (therapeutic use)